Cargando…

Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is a common and deadly cancer worldwide and is often refractory to chemotherapy due to the development of multidrug resistance. Lonafarnib is an orally active and potent non-peptidomimetic inhibitor of farnesyl transferase. Here, using in vitro HCC cell models, we demo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jialiang, Lian, Yifan, Gu, Yurong, Wang, Hongbo, Gu, Lin, Huang, Yanlin, Zhou, Liang, Huang, Yuehua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739619/ https://www.ncbi.nlm.nih.gov/pubmed/29285232 http://dx.doi.org/10.18632/oncotarget.22086

Ejemplares similares

The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells
por: Wang, Jialiang, et al.
Publicado: (2019)

Correction for: The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells
por: Wang, Jialiang, et al.
Publicado: (2019)

Farnesyl Transferase Inhibitor Lonafarnib Enhances α7nAChR Expression Through Inhibiting DNA Methylation of CHRNA7 and Increases α7nAChR Membrane Trafficking
por: Chen, Tingting, et al.
Publicado: (2020)

Lonafarnib: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Lonafarnib Is a Potential Inhibitor for Neovascularization
por: Sun, Linlin, et al.
Publicado: (2015)

GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis
por: Wu, Xiaojuan, et al.
Publicado: (2017)

Use of Farnesyl Transferase Inhibitors in an Ageing Model in Drosophila
por: Brandt, Annely, et al.
Publicado: (2023)

Correlations between cytokines produced by T cells and clinical-virological characteristics in untreated chronic hepatitis B patients
por: Gu, Yurong, et al.
Publicado: (2019)

Correction to: Lonafarnib: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Upregulation of kinesin family member 4A enhanced cell proliferation via activation of Akt signaling and predicted a poor prognosis in hepatocellular carcinoma
por: Huang, Yanlin, et al.
Publicado: (2018)

Downregulated Trophinin-Associated Protein Plays a Critical Role in Human Hepatocellular Carcinoma Through Upregulation of Tumor Cell Growth and Migration
por: Lian, Yifan, et al.
Publicado: (2018)

Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas
por: Kessler, Linda, et al.
Publicado: (2021)

CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma
por: Gu, Yurong, et al.
Publicado: (2020)

Molecular docking and simulation of Curcumin with Geranylgeranyl Transferase1 (GGTase1) and Farnesyl Transferase (FTase)
por: Subramani, Parasuraman Aiya, et al.
Publicado: (2015)

Prognostic roles of the transcriptional expression of exportins in hepatocellular carcinoma
por: Chen, Lubiao, et al.
Publicado: (2019)

Overexpressing CCT6A Contributes To Cancer Cell Growth By Affecting The G1-To-S Phase Transition And Predicts A Negative Prognosis In Hepatocellular Carcinoma
por: Zeng, Guofen, et al.
Publicado: (2019)

Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas
por: Field, Kenneth A, et al.
Publicado: (2008)

Lonafarnib Inhibits Farnesyltransferase via Suppressing ERK Signaling Pathway to Prevent Osteoclastogenesis in Titanium Particle-Induced Osteolysis
por: Huang, Linke, et al.
Publicado: (2022)

Serum HBV pregenomic RNA is correlated with Th1/Th2 immunity in treatment‐naïve chronic hepatitis B patients
por: Gu, Yurong, et al.
Publicado: (2019)

Discovery of Lonafarnib-Like Compounds: Pharmacophore Modeling and Molecular Dynamics Studies
por: Rampogu, Shailima, et al.
Publicado: (2020)

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor
por: Sparreboom, A, et al.
Publicado: (2004)

Breast Cancer Stem Cells Survive Periods of Farnesyl-Transferase Inhibitor-Induced Dormancy by Undergoing Autophagy
por: Chaterjee, Moumita, et al.
Publicado: (2011)

HBV core promoter mutations and AKT upregulate S-phase kinase-associated protein 2 to promote postoperative hepatocellular carcinoma progression
por: Chen, Lubiao, et al.
Publicado: (2016)

Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B
por: Gu, Yurong, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection
por: Canini, Laetitia, et al.
Publicado: (2017)

Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells
por: Arnold, Rouven, et al.
Publicado: (2021)

Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells
por: Paolo, A Di, et al.
Publicado: (2001)

Suppression of Human Pancreatic Cancer Growth in BALB/c Nude Mice by Manumycin, a Farnesyl:protein Transferase Inhibitor
por: Ito, Toshio, et al.
Publicado: (1996)

Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells
por: Wang, Fang, et al.
Publicado: (2015)

Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome
por: Murtada, Sae-Il, et al.
Publicado: (2023)

Veritable antiviral capacity of natural killer cells in chronic HBV infection: an argument for an earlier anti-virus treatment
por: Li, Xiaoyan, et al.
Publicado: (2017)

Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer
por: Rich, Tyvin A, et al.
Publicado: (2012)

Synergistic Effects of Plant Derivatives and Conventional Chemotherapeutic Agents: An Update on the Cancer Perspective
por: Pezzani, Raffaele, et al.
Publicado: (2019)

Transformation by Hras(G12V) is Consistently Associated with Mutant Allele Copy Gains and is Reversed by Farnesyl Transferase Inhibition
por: Chen, Xu, et al.
Publicado: (2013)

Chemotherapeutic Agents for the Treatment of Hepatocellular Carcinoma: Efficacy and Mode of Action
por: Shaaban, Saad, et al.
Publicado: (2014)

Blockage of CacyBP inhibits macrophage recruitment and improves anti-PD-1 therapy in hepatocellular carcinoma
por: Wang, Jialiang, et al.
Publicado: (2023)

Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review
por: Eitsuka, Takahiro, et al.
Publicado: (2016)

Evaluation of Chemotherapeutic Agents
por: Engstrom, W. W.
Publicado: (1949)

Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways
por: Dalenc, Florence, et al.
Publicado: (2005)

Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor
por: Gu, Ming, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_onq5gl0jd1je7vorii6644kns9